Search Results - "Blaisse, Reinoud J B"

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial by Shapiro, Joel, Dr, van Lanschot, J Jan B, Prof, Hulshof, Maarten C C M, MD, van Hagen, Pieter, MD, van Berge Henegouwen, Mark I, MD, Wijnhoven, Bas P L, MD, van Laarhoven, Hanneke W M, Prof, Nieuwenhuijzen, Grard A P, MD, Hospers, Geke A P, Prof, Bonenkamp, Johannes J, MD, Cuesta, Miguel A, Prof, Blaisse, Reinoud J B, MD, Busch, Olivier R C, Prof, ten Kate, Fiebo J W, Prof, Creemers, Geert-Jan M, MD, Punt, Cornelis J A, Prof, Plukker, John Th M, Prof, Verheul, Henk M W, Prof, Bilgen, Ernst J Spillenaar, MD, van Dekken, Herman, MD, van der Sangen, Maurice J C, MD, Rozema, Tom, MD, Biermann, Katharina, MD, Beukema, Jannet C, MD, Piet, Anna H M, MD, van Rij, Caroline M, MD, Reinders, Janny G, MD, Tilanus, Hugo W, Prof, Steyerberg, Ewout W, Prof, van der Gaast, Ate, MD

“…Summary Background Initial results of the ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) comparing neoadjuvant chemoradiotherapy…”
Get full text

Cardiac monitoring during adjuvant trastuzumab therapy: Guideline adherence in clinical practice by Visser, Annemiek, van de Ven, Eline M W, Ruczynski, Larissa I A, Blaisse, Reinoud J B, van Halteren, Henk K, Aben, Katja, van Laarhoven, Hanneke W M

“…Cardiotoxicity is an important adverse effect of adjuvant breast cancer treatment with trastuzumab and three monthly left ventricular ejection fraction (LVEF)…”
Get more information

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial by Eyck, Ben M, van Lanschot, J Jan B, Hulshof, Maarten C C M, van der Wilk, Berend J, Shapiro, Joel, van Hagen, Pieter, van Berge Henegouwen, Mark I, Wijnhoven, Bas P L, van Laarhoven, Hanneke W M, Nieuwenhuijzen, Grard A P, Hospers, Geke A P, Bonenkamp, Johannes J, Cuesta, Miguel A, Blaisse, Reinoud J B, Busch, Olivier R, Creemers, Geert-Jan M, Punt, Cornelis J A, Plukker, John Th M, Verheul, Henk M W, Spillenaar Bilgen, Ernst J, van der Sangen, Maurice J C, Rozema, Tom, Ten Kate, Fiebo J W, Beukema, Jannet C, Piet, Anna H M, van Rij, Caroline M, Reinders, Janny G, Tilanus, Hugo W, Steyerberg, Ewout W, van der Gaast, Ate

“…Preoperative chemoradiotherapy according to the chemoradiotherapy for esophageal cancer followed by surgery study (CROSS) has become a standard of care for…”
Get full text

Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial by Noordman, Bo Jan, Verdam, Mathilde G E, Lagarde, Sjoerd M, Hulshof, Maarten C C M, van Hagen, Pieter, van Berge Henegouwen, Mark I, Wijnhoven, Bas P L, van Laarhoven, Hanneke W M, Nieuwenhuijzen, Grard A P, Hospers, Geke A P, Bonenkamp, Johannes J, Cuesta, Miguel A, Blaisse, Reinoud J B, Busch, Olivier R, Ten Kate, Fiebo J W, Creemers, Geert-Jan M, Punt, Cornelis J A, Plukker, John Th M, Verheul, Henk M W, Spillenaar Bilgen, Ernst J, van Dekken, Herman, van der Sangen, Maurice J C, Rozema, Tom, Biermann, Katharina, Beukema, Jannet C, Piet, Anna H M, van Rij, Caroline M, Reinders, Janny G, Tilanus, Hugo W, Steyerberg, Ewout W, van der Gaast, Ate, Sprangers, Mirjam A G, van Lanschot, J Jan B

“…Purpose To compare pre-agreed health-related quality of life (HRQOL) domains in patients with esophageal or junctional cancer who received neoadjuvant…”
Get full text

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial by Cats, Annemieke, Jansen, Edwin P M, van Grieken, Nicole C T, Sikorska, Karolina, Lind, Pehr, Nordsmark, Marianne, Meershoek-Klein Kranenbarg, Elma, Boot, Henk, Trip, Anouk K, Swellengrebel, H A Maurits, van Laarhoven, Hanneke W M, Putter, Hein, van Sandick, Johanna W, van Berge Henegouwen, Mark I, Hartgrink, Henk H, van Tinteren, Harm, van de Velde, Cornelis J H, Verheij, Marcel, Van Coevorden, Frits, Vanhoutvin, Steven, Hulshof, Maarten CCM, Loosveld, Olaf JL, Ten Tije, A (Bert) Jan, Erdkamp, Frans LG, Warmerdam, Fabienne ARM, Van der Peet, Donald L, Verheul, Henk MW, Boerma, Djamila, Los, Maartje, Slot, Annerie, Houtsma, Danny, Portielje, Johanna EA, Blaisse, Reinoud JB, Spillenaar Bilgen, Ernst Jan, Polée, Marco B, Geenen, Maud M, Braak, Jeffrey PBM, Neelis, Karen J, Slingerland, Marije, Jansen, Rob LH, Buijsen, Jeroen, Beeker, Aart, Eijsbouts, Quirijn AJ, Van Riel, Johanna MGH, Rozema, Tom, Van Spronsen, Dick Johan, Meerum Terwogt, Jetske M, Tanis, Bea C, Van der Torren-Conze, Adelheid ME, Van Hilligersberg, Richard, Koopman, Miriam, Den Boer, Marien O, Creemers, Geert-Jan, Van der Sangen, Maurice, Rentinck, Marjolein EM, Van den Berg, H Pieter, Jonkers, Ge JPM, Grootenboers, Diane, Vulink, Annelie JE, Hovenga, Sjoerd, Van der Mijle, Huub CJ, Baars, Arnold, Haringhuizen, Annebeth W, Appels, Marije IE, Rietbroek, Ron C, Hendriksen, Ellen M, Legdeur, Marie-Cecile JC, Ten Bokkel Huinink, Daan, Van Dobbenburgh, O Aart, Smit, Jitty M, Van Bochove, Aart, Veldhuis, Gerrit-Jan, Muller, Erik W, Bonenkamp, J (Han) J, Braam, Pètra M, De Boer, Jaap, Van Halteren, Henk K, Valster, Fransje AA, Imholz, Alex LT, Van Dijk, Marjan A, Van der Gaast, Ate, Otten, J (Hans)-Martin MB, Ceha, Heleen M, Glimelius, Bengt, Lagerbäck, Cecillia, Perman, Mats, Johnsson, Anders, Borg, David, Nielsen, Niels H, Piwowar, Andrzej, Elmlund, Mattias, Hörberg, Helene, Edlund, Per, Johansson, Bengt, Flygare, Petra, Jespersen, Marie Louise

“…Both perioperative chemotherapy and postoperative chemoradiotherapy improve survival in patients with resectable gastric cancer from Europe and North America…”
Get full text

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial by Petrylak, Daniel P, de Wit, Ronald, Chi, Kim N, Drakaki, Alexandra, Sternberg, Cora N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed A, Fléchon, Aude, van der Heijden, Michiel S, Matsubara, Nobuaki, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan Senol, Su, Wen-Pin, Percent, Ivor J, Lee, Jae-Lyun, Laestadius, Fredrik, Peer, Avivit, Garcia del Muro, Xavier, Cicin, Irfan, Vaishampayan, Ulka, Aragon-Ching, Jeanny B, Hamid, Oday, Wijayawardana, Sameera, Russo, Francesca, Zimmermann, Annamaria H, Bell-McGuinn, Katherine M, Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Wan Ng, Siobhan Su, Rutten, Annemie, Dumez, Herlinde, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Joly, Florence, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Karavasilis, Vasilis, Révész, Janos, Leibowitz-Amit, Raya, Kejzman, Daniel, Sarid, David, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Oyama, Masafumi, Yonese, Junji, Uemura, Motohide, Tsunemori, Hiroyuki, Yokomizo, Akira, Nagamori, Satoshi, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Vazquez Cortés, Leticia, Lorena Urzua Flores, Claudia, Blaisse, Reinoud J.B., Aarts, Maureen J.B., Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Fomkin, Roman, Grande, Enrique, Lin, Chia-Chi, Yeh, Su-Peng, Erman, Mustafa, Urun, Yuksel, Golovko, Yuriy, Sinielnikov, Ivan, Crabb, Simon J., Syndikus, Isabel, Sundar, Santhanam, Pan, Chong Xian, Schwarz, James K., Acs, Peter Istvan, Hainsworth, John D., Lawler, William Eyre

“…Ramucirumab—an IgG1 vascular endothelial growth factor receptor 2 antagonist—plus docetaxel was previously reported to improve progression-free survival in…”
Get full text

O200 10-YEAR FOLLOW-UP OF A RANDOMISED CONTROLLED TRIAL COMPARING NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY VERSUS SURGERY ALONE FOR OESOPHAGEAL OR JUNCTIONAL CANCER (CROSS) by Eyck, Ben M, van Lanschot, J Jan B, Hulshof, Maarten C C M, van der Wilk, Berend J, Shapiro, Joel, van Hagen, Pieter, Nieboer, Daan, van Berge Henegouwen, Mark I, Wijnhoven, Bas P L, van Laarhoven, Hanneke W M, Nieuwenhuijzen, Grard A P, Hospers, Geke A P, Bonenkamp, Johannes J, Cuesta, Miguel A, Blaisse, Reinoud J B, Busch, Olivier R, ten Kate, Fiebo J W, Creemers, Geert-Jan M, Punt, Cornelis J A, Plukker, John Th M, Verheul, Henk M W, Spillenaar Bilgen, Ernst J, van Dekken, Herman, van der Sangen, Maurice J C, Rozema, Tom, Biermann, Katharina, Beukema, Jannet C, Piet, Anna H M, van Rij, Caroline M, Reinders, Janny G, Tilanus, Hugo W, van der Gaast, Ate

“…Abstract Aim To report the long term results of the CROSS trial with a minimum follow-up of 10 years. Background Neoadjuvant chemoradiotherapy according to the…”
Get full text